	US 11,701,388 B2
	Thrombosomes as an antiplatelet agent reversal agent
Keith Andrew Moskowitz, Westfield, IN (US); Braden Carl Ishler, Montgomery Village, MD (US); William Matthew Dickerson, Washington, DC (US); Narendra Nath Tandon, Gaithersburg, MD (US); Amber Nicole Lee, Montgomery Village, MD (US); and Glen Michael Fitzpatrick, North Potomac, MD (US)
Assigned to Cellphire, Inc., Rockville, MD (US)
Filed by Cellphire, Inc., Rockville, MD (US)
Filed on Aug. 14, 2020, as Appl. No. 16/994,377.
Claims priority of provisional application 63/065,337, filed on Aug. 13, 2020.
Claims priority of provisional application 62/887,923, filed on Aug. 16, 2019.
Prior Publication US 2021/0046121 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/19 (2015.01); A61P 7/04 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01)

CPC A61K 35/19 (2013.01) [A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61P 7/04 (2018.01)]

22 Claims

1. A method of treating a coagulopathy in a subject, the method comprising administering to a human subject in need thereof, an effective amount of a rehydrated composition comprising freeze-dried platelet derivatives (FDPDs) and an incubating agent comprising one or more salts and a buffer,

wherein the human subject is being treated with an antiplatelet agent selected from the group consisting of cangrelor, ticagrelor, prasugrel, abciximab, terutroban, picotamide, elinogrel, vorapaxar, atopaxar, cilostazol, epoprostenol, dipyridamole, treprostinil sodium, sarpogrelate, clopidogrel, eptifibatide, tirofiban, and ticlopidine, such that treatment with the antiplatelet agent is continued before and after the administering without stopping the treatment;

wherein the administering comprises administering parenterally, intravenously, intramuscularly, intrathecally, subcutaneously, or intraperitoneally; and

wherein the effective amount of the composition is at least 1.0×10⁸FDPDs/kg of the human subject.